Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Ca...( Ash Stevens ...)

Ash Stevens, Incorporated (ASI), a full service contract drug development and cGMP manufacturer, announced that the company is in the initial phases of a multi-year $6 million expansion project to upgrade the capacity and capabilities of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Riverview, Michigan. Expansions will include a new reactor bay and warehouse.

Detroit, MI (PRWEB) September 30, 2009 -- Ash Stevens, Incorporated (ASI), a full service contract drug development and cGMP manufacturer, announced that the company is in the initial phases of a multi-year expansion project to upgrade the capacity and capabilities of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Riverview, Michigan. Expenditures for the initial phases of the project will total more than $6 million and will include a new reactor bay and warehouse. The investment will add significant capacity and additional capabilities to the existing ASI facility as part of ASI's on-going commitment to provide the company's clients with the highest quality of service, safety, and on-time delivery of APIs.

To be operational in January 2010, the plan's initial phase calls for an isolated new reactor bay, which will house two 100-gallon glass-lined reactors and a 50-gallon hydrogenation vessel. The new reactor bay will provide redundant capacity to a similarly designed existing bay that holds three 100-gallon reactors, while providing additional plant capacity and plant-scale hydrogenation capabilities.

In June of 2010, ASI will occupy a new 10,000 square foot warehouse facility. Completion of the state-of-the-art reactor bay and warehouse facility will set the stage for execution of the next phases of the expansion plan.

"The new bay and warehouse represent a self-financed $6 million investment for ASI. The continuous upgrading and modernization of our
'/>"/>